Seneca Therapeutics Announces Publication of AACR Abstract Demonstrating Systemic Anti-Tumor Immune Response in Syngeneic Pancreatic Murine Model

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of oncolytic immune-therapeutics based on Seneca Valley Virus (SVV-001), announced today the publication of an abstract Oncolytic Seneca Valley Virus (SVV-001) overcomes checkpoint inhibitor resistance and demonstrates a systemic anti-tumor immune response in a syngeneic pancreatic cancer murine model at the upcoming American Association for Cancer Research meeting in New Orleans, LA.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Wednesday, March 9, 2022
Information
Tags: 
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Genome, Forward-looking statement, Pancreatic cancer, Senecavirus, Therapy, American Association, Association, Seneca, American Association for Cancer Research
Geotags: 
UNITED STATES, NORTH AMERICA, LOUISIANA, PENNSYLVANIA, LA, NEW ORLEANS
Summary
Key Points: 
  • Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of oncolytic immune-therapeutics based on Seneca Valley Virus (SVV-001), announced today the publication of an abstract Oncolytic Seneca Valley Virus (SVV-001) overcomes checkpoint inhibitor resistance and demonstrates a systemic anti-tumor immune response in a syngeneic pancreatic cancer murine model at the upcoming American Association for Cancer Research meeting in New Orleans, LA.
  • The abstract will be presented by Dr. Paul Hallenbeck, one of the authors of the publication.
  • Seneca Therapeutics was founded by Dr. Paul Hallenbeck to develop SVV-001.
  • This press release contains forward-looking statements concerning the development of Seneca Therapeutics products, the potential benefits and attributes of those products, and the companys expectations regarding its prospects.


Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of oncolytic immune-therapeutics based on Seneca Valley Virus (SVV-001), announced today the publication of an abstract “Oncolytic Seneca Valley Virus (SVV-001) overcomes checkpoint inhibitor resistance and demonstrates a systemic anti-tumor immune response in a syngeneic pancreatic cancer murine model” at the upcoming American Association for Cancer Research meeting in New Orleans, LA.

The abstract will be presented by Dr. Paul Hallenbeck, one of the authors of the publication. The permanent abstract number is #6218. The presentation will be available starting April 8.

About Seneca Therapeutics

Seneca Therapeutics was founded by Dr. Paul Hallenbeck to develop SVV-001. Seneca Therapeutics is also developing armed versions of SVV-001 that will selectively express gene product(s) that are inserted into the genome of SVV-001 and create additional anti-tumor effects.

Forward-Looking Statements

This press release contains “forward-looking statements” concerning the development of Seneca Therapeutics products, the potential benefits and attributes of those products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Seneca Therapeutics undertakes no obligation to update any forward-looking statements for any reason.

Copyright: 
Copyright Business Wire 2022